Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals

American Journal on Addictions

Volumn 23, Issue 1, 2014, Pages 34-40

  Masson, Carmen L ^a   Rainey, Petrie M ^b   Moody, David E ^c   McCance Katz, Elinore F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMPHETAMINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUPRENORPHINE; BUPRENORPHINE 3 GLUCURONIDE; BUPRENORPHINE PLUS NALOXONE; DRUG METABOLITE; NORBUPRENORPHINE; NORBUPRENORPHINE 3 GLUCURONIDE; PROTEIN; UNCLASSIFIED DRUG; HEPATITIS C ANTIBODY; NALOXONE; NARCOTIC ANTAGONIST;

ADULT; ALCOHOL ABUSE; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANNABIS ADDICTION; CLINICAL ARTICLE; COCAINE DEPENDENCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; OPIATE ADDICTION; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; BLOOD; CASE CONTROL STUDY; COMPLICATION; OPIOID-RELATED DISORDERS; VIROLOGY; YOUNG ADULT;

ADULT; BUPRENORPHINE; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84890099630     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2013.12052.x     Document Type: Article

References (26)

1. McCance-Katz E., Office based treatment of opioid dependence with buprenorphine. Harv Rev Psychiatry. 2004; 12: 321-338.
2. Lange WR, Fudala PJ, Dax EM, et al. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. 1990; 26: 19-28.
3. Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. 2000; 9: 265-269.
4. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human t-lymphotropic viruses. Am J Public Health. 1996; 86: 655-661.
5. Thiede H, Hagan H, Murrill CS., Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000; 77: 331-345.
6. Neaigus A, Gyarmathy VA, Miller M, et al. Injecting and sexual risk correlates of HBV and HCV seroprevalence among new injectors. Drug Alcohol Depend. 2007; 89: 234-243.
7. Tseng F, O'Brien TR, Zhang M, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users. Hepatology. 2007; 46: 666-671.
8. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States. Clin Infect Dis. 2008; 46: 1852-1858.
9. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: A prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009; 200: 1216-1226.
10. Burke KP, Cox AL., Hepatitis C virus evasion of adaptive immune responses-a model for viral persistence. Immunol Res. 2010; 47: 216-227.
11. Baker J, Rainey PM, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudinand tenofovir. Am J Addict. 2010; 19: 17-29.
12. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006; 43 (Suppl. 4): S224-S234.
13. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis. 2006; 43 (Suppl. 4): S235-S246.
14. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007; 91: 269-278.
15. McCance-Katz EF, Moody DE, Morse GD, et al. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict. 2010; 19: 30-37.
16. Moody DE, Fang WB, Morrison J, et al. Gender differences in pharmacokinetics of maintenance-dosed buprenorphine. Drug Alcohol Depend. 2011; 118: 479-483.
17. Chiang CN, Hawks RL., Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003; 70: S39-S47.
18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38: 518-526.
19. Huang W, Moody DE, McCance-Katz EF., The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- eletrospray ionization-tandem mass spectrometry. Ther Drug Monit. 2006; 28: 245-251.
20. Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984; 12: 577-581.
21. Chang Y, Moody DE, McCance-Katz EF., Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006; 34: 440-448.
22. Elkader A, Sproule B., Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005; 44: 661-680.
23. +-taurocholate- cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos. 2008; 36: 1786-1793.
24. Zhang W, Ramamoorthy Y, Tyndale RF, et al. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003; 31: 768-772.
25. Zuin M, Giorgini A, Selmi C, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Digest Liver Dis. 2009; 41: e8-e10.
26. Te HS, Jensen DM., Epidemiology of hepatitis B and C virus: A global overview. Clin Liver Dis. 2010; 14: 1-21.